SCHEDULE: Vanguard Group Reports 0% Stake in Vanda Pharma

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Vanda Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 7 to Schedule 13G for Vanda Pharmaceuticals Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0% of Vanda Pharmaceuticals Inc.'s Common Stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will report beneficial ownership separately, in reliance on SEC Release No. 34-39538 (January 12, 1998).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities now reported by these disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Vanda Pharmaceuticals Inc., as it primarily reflects an internal reporting realignment by The Vanguard Group rather than a change in investment thesis or a divestment based on the issuer's performance.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• No one other person's interest in the securities reported herein is more than 5%.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional investors like The Vanguard Group frequently adjust their reporting structures and beneficial ownership disclosures. This particular filing reflects an internal organizational change at Vanguard, leading to a disaggregation of reporting, rather than a direct investment decision regarding Vanda Pharmaceuticals Inc. It highlights the ongoing evolution of reporting requirements and internal structures within large asset management firms.

Stakeholder Impact

• Shareholders of Vanda Pharmaceuticals Inc. may see a change in the reported institutional ownership figures, but this specific filing does not indicate a change in the underlying investment by Vanguard's clients, only how it is reported.
• The Vanguard Group's internal realignment impacts its own reporting structure and how its various funds and divisions disclose their holdings.

Key Dates

Recommendation

This filing is a routine amendment to a Schedule 13G, reflecting an internal organizational change at The Vanguard Group rather than a change in investment strategy or a significant divestment from Vanda Pharmaceuticals Inc. As such, it provides no new information that would warrant a change in investment recommendation for Vanda Pharmaceuticals Inc. A "hold" recommendation is appropriate as there's no fundamental news to alter the investment thesis.

Keywords

Vanda Pharmaceuticals Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Investment Adviser, Ownership Change